PTHS Chromocell Therapeutics Corp Insider Trading

Director Todd C Davis purchases 35,948 shares for $999,983.28 at blended average $27.82 despite current price $26.50.

Todd C Davis acquired 35,948 shares across 2 separate purchases totaling $999,983.28 at a blended average price of $27.82, occurring on 2026-06-11 when the stock was trading approximately $27.80–$28.73. The purchase doubled his holdings from 39,886 shares to 75,834 shares (+90.1%), representing a substantial personal capital commitment of approximately one million dollars in a company with recent quarterly revenue of $10,906,000 and negative net income of $-10,238,000. The transaction occurred when the current price of $26.50 is down 51.2% from the 52-week high of $54.29, and the stock has declined 0.8% over the past 30 days despite a +11.1% gain over 90 days. Across his cross-ticker open-market history, Davis demonstrates a 100% win rate on prior buys over the 90-day horizon (5 prior transactions averaging +31.5% return), though this specific company is unprofitable and the recent buying price sits materially above current levels.

CHRO CEO purchased 5,200 shares at $0.97 across 2 transactions (Sep 10-13); stock at $8.50, down 82.3% from 52-week high.

Francis Knuettel II, serving as CEO, President, CFO, Treasurer and Secretary, executed 2 separate purchases totaling 5,200 shares for $5,044.00 at $0.97 per share on 2024-09-12 and 2024-09-13, adding 1.0% to his 542.5K share baseline. The stock currently trades at $8.50, representing an 82.3% decline from its 52-week high of $48.00, although it has recovered 7.6% over the prior 30 days. The company reported net income of -$1,771,619.00 for its most recent full fiscal year. Knuettel's cross-ticker track record shows only 2 prior open-market buys, and prior trades at CHRO (executed on 2024-09-10 and 2024-09-11) remain too recent for outcome measurement. The purchases occurred during a period of significant stock weakness, though without scheduled trading plan documentation, timing cannot be characterized as either well-timed or discretionary conviction.

Director Malamut buys 10,400 shares at $0.94 amid stock down -82.3% from 52-week high of $48.00

Director Richard Malamut purchased 10,400 shares at $0.94 on 2024-09-12, adding to holdings that now stand at 91,565 shares post-transaction. The purchase occurs at a price far removed from the stock's 52-week high of $48.00 — the current price of $8.50 is -82.3% below that peak, suggesting a sustained period of significant stock deterioration. The company reported full-year net income of $-1,771,619.00, indicating persistent unprofitability, which contextualizes the downward price movement as driven by fundamental weakness rather than temporary sentiment. The transaction represents a modest position increase of 10,400 shares against existing holdings, noteworthy chiefly because it occurs in an environment of deep underperformance and negative earnings, where the economic rationale for accumulation is not immediately apparent.

CEO/CFO Francis Knuettel II buys 12,000 shares at $0.91 blended price vs. current $9.80 (stock -79.6% from 52-week high)

Francis Knuettel II, holding multiple executive roles (CEO, President, CFO, Treasurer, Secretary), purchased 12,000 shares across 2 separate transactions on 2024-09-10 and 2024-09-11 at a blended average price of $0.91, increasing his holdings from 530.5K to 542.5K shares (+2.3%). The timing is notable: Chromocell is unprofitable (net income of $-1.8M) and currently trades at $9.80, representing a steep 79.6% decline from its 52-week high of $48.00. The stock has rebounded +28.1% over the prior 30 days but remains -24.6% over 90 days. This is his first prior buy on record across his open-market history, limiting the ability to assess his execution pattern at this ticker or cross-ticker. The magnitude of the position increase (+2.3%) combined with material execution at distressed price levels during a period of significant stock volatility warrants monitoring of whether this reflects a point-of-confidence decision by a multi-hat executive or a temporary technical bounce in a fundamentally challenged name.